179 related articles for article (PubMed ID: 10603732)
1. [Community-acquired respiratory tract infections. Current data on the efficacy of various classes of antibiotics and antibiotic resistance of the main prevalent bacteria species].
Marre R; Trautmann M
Med Klin (Munich); 1999 Nov; 94(11):609-13. PubMed ID: 10603732
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
Richard MP; Aguado AG; Mattina R; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
[TBL] [Abstract][Full Text] [Related]
3. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
Pfaller MA; Ehrhardt AF; Jones RN
Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
Koeth LM; Jacobs MR; Bajaksouzian S; Zilles A; Lin G; Appelbaum PC
Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
Blondeau JM; Vaughan D; Laskowski R; Borsos S;
Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
[TBL] [Abstract][Full Text] [Related]
7. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
[TBL] [Abstract][Full Text] [Related]
8. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
Felmingham D
J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
Jones RN; Biedenbach DJ
Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
Mendes C; Marin ME; Quiñones F; Sifuentes-Osornio J; Siller CC; Castanheira M; Zoccoli CM; López H; Súcari A; Rossi F; Angulo GB; Segura AJ; Starling C; Mimica I; Felmingham D
Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
Gordon KA; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
[TBL] [Abstract][Full Text] [Related]
12. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
13. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections.
Ehrhardt AF; Russo R
Am J Med; 2001 Dec; 111 Suppl 9A():30S-35S discussion 36S-38S. PubMed ID: 11755441
[TBL] [Abstract][Full Text] [Related]
14. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
15. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
Critchley IA; Brown SD; Traczewski MM; Tillotson GS; Janjic N
Antimicrob Agents Chemother; 2007 Dec; 51(12):4382-9. PubMed ID: 17908940
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Pontani D; Washton H; Bouchillon S; Johnson J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
[TBL] [Abstract][Full Text] [Related]
17. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens' antibacterial susceptibility.
Niki Y; Hanaki H; Matsumoto T; Yagisawa M; Kohno S; Aoki N; Watanabe A; Sato J; Hattori R; Koashi N; Terada M; Kozuki T; Maruo A; Morita K; Ogasawara K; Takahashi Y; Matsuda K; Nakanishi K; Sunakawa K; Takeuchi K; Fujimura S; Takeda H; Ikeda H; Sato N; Niitsuma K; Saito M; Koshiba S; Kaneko M; Miki M; Nakanowatari S; Takahashi H; Utagawa M; Nishiya H; Kawakami S; Aoki Y; Chonabayashi N; Sugiura H; Ichioka M; Goto H; Kurai D; Saraya T; Okazaki M; Yoshida K; Yoshida T; Tsukada H; Imai Y; Honma Y; Yamamoto T; Kawai A; Mikamo H; Takesue Y; Wada Y; Miyara T; Toda H; Mitsuno N; Fujikawa Y; Nakajima H; Kubo S; Ohta Y; Mikasa K; Kasahara K; Koizumi A; Sano R; Yagi S; Takaya M; Kurokawa Y; Kusano N; Mihara E; Nose M; Kuwabara M; Fujiue Y; Ishimaru T; Matsubara N; Kawasaki Y; Tokuyasu H; Masui K; Kido M; Ota T; Honda J; Kadota J; Hiramatsu K; Aoki Y; Nagasawa Z; Yanagihara K; Fujita J; Tateyama M; Totsuka K
J Infect Chemother; 2011 Aug; 17(4):510-23. PubMed ID: 21409533
[TBL] [Abstract][Full Text] [Related]
18. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
[TBL] [Abstract][Full Text] [Related]
19. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
